查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1807535

果冻市场按产品类型、材料类型、吸收性、应用和最终用户划分－2025-2030 年全球预测

Biosurgery Market by Product Type, Material Type, Resorbability, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年果冻市场价值将达到 171.5 亿美元，2025 年成长至 185.8 亿美元，复合年增长率为 8.48%，到 2030 年将达到 279.6 亿美元。

主要市场统计数据
基准年2024年 171.5亿美元
预计2025年 185.8亿美元
预测年份 2030 279.6亿美元
复合年增长率（%） 8.48%

果冻已成为现代医疗保健的关键领域，它整合生物活性材料，用于支持各种外科手术中的组织修復、止血和粘连。微创手术需求的不断增长，加上生物材料科学的进步，推动该领域走在技术创新的前沿。相关人员正在应对一个动态的环境，其特点是法律规范不断演变、成本限制日益增加，以及需要在日益复杂的患者群体中证明临床疗效。

果冻的创新步伐得益于材料科学家、工程师和临床专家之间的跨学科合作，他们致力于优化性能和安全性。将新型胶原蛋白、纤维蛋白和合成基质转化为可扩展的产品需要严格的检验，并与现有的外科工作流程进行週详的整合。同时，监管机构正在完善途径，以平衡病人安全和及时获取，鼓励製造商积极参与对话并提供证据。

本执行摘要全面阐述了塑造果冻市场的变革力量，包括技术突破、政策发展以及医疗保健提供者优先事项的转变。它还阐明了近期关税调整的影响，剖析了产品类型、材料、可吸收性特征、临床用途和最终用户环境等核心细分维度，并揭示了细緻入微的区域动态。读者将获得关于竞争定位、伙伴关係机会以及未来关键决策点的策略清晰资讯。

绘製推动果冻创新和重塑全球医疗保健产业竞争格局的模式转移

近年来，随着先进的止血剂、生物黏合剂和组织移植技术的出现，果冻经历了一场颠覆性的变革，这些技术提供了卓越的生物相容性和动态精度。纤维蛋白基密封剂和合成聚合物的创新为有效止血和组织再生开闢了新的途径。此外，多学科研究倡议正在推动下一代复合材料的开发，这些复合材料整合了抗菌和生长因子功能，以简化术后恢復。

评估2025年美国关税调整对生物外科供应果冻、成本结构和策略采购实务的连锁反应

美国当局实施的2025年修订关税表，为从国际供应商采购的生物外科材料和设备引入了新的成本维度。这些调整加强了对进口价格的审查，迫使製造商重新评估其供应商选择和供应链架构。因此，采购团队正在探索各种采购模式，例如近岸外包和区域合作，以稳定投入成本并缓解全球贸易中断造成的波动。

确定核心细分框架，确定果冻产品、材料、可吸收性、应用和最终用户概况的多样化途径

产品类型的分析显示，止血剂、封闭剂和黏合剂以及组织移植物的发展轨迹各不相同。止血剂不断发展，吸收动力学得到改善，给药方式也更具客製化，以应对高风险手术中的出血挑战。封闭剂和黏合剂的配方兼具强大的黏合强度和生物相容性的载体系统，使其受益匪浅。组织移植物，包括细胞基质和细胞化结构，正在不断改进，以改善整个外科领域的整合和功能恢復。

解读影响美洲、中东和非洲以及亚太地区果冻成长轨迹的区域趋势

在美洲，对医疗基础设施的大力投资以及对微创手术的关注正在推动市场成长。北美的监管支持和报销框架正在推动高端生物外科产品的普及，而拉丁美洲市场则正透过有针对性的官民合作关係和能力建设倡议蓬勃发展。这种区域多样性为製造商创造了机会，他们可以根据不同的资源环境和患者可及性因素来客製化产品组合。

主要企业的策略性倡议和创新管道：尖端解决方案和合作伙伴关係，开拓竞争前沿

领先的果冻公司正在推行差异化策略，以保持竞争优势。一些公司优先收购利基技术公司，以增强产品平臺，并累积新型生物材料和先进输送系统的专业知识。另一些公司则投入资源进行内部研发，并建立专门的研发中心，探索下一代复合材料和生物活性支架。与学术机构和受託研究机构的合作也促进了探索性研究，为未来的产品上市提供支援。

为行业领导者提供实用建议，以避免中断、利用技术进步并确立果冻市场的领导地位

投资于适应性强的供应链策略对于企业应对不断变化的贸易环境至关重要。建立多条采购管道，包括区域製造中心和合格的合约合作伙伴，可以缓解价格波动和物流瓶颈。主动与海关部门和认证机构沟通，也可以简化进口流程，避免代价高昂的延误。在采购框架中建立弹性，可以帮助企业保障业务连续性，并保护利润率免受未来地缘政治波动的影响。

严格的多方法调查方法的详细信息，该方法结合了主要见解、二次分析和定量模型，揭示了果冻市场的真实本质

本研究整合了多方法研究框架，结合主要相关人员访谈、二手文献分析和量化建模，全面涵盖果冻领域。透过与外科医生、采购专家、监管专家和产品经理的深入交流，我们获得了关于未满足需求、创新驱动力和应用障碍的第一手观点。同时，我们也对已发表的临床试验、专利申请和政策白皮书进行了系统性回顾，以丰富研究背景，并促进定性资料与文献证据的三角检验。

彙编关键发现和策略结论，为不断发展的果冻系统中的相关人员阐明前进的道路

综上所述，本摘要重点分析描绘了果冻领域在快速技术创新与经济力量转变交会的景象。先进的材料和专用输送系统正在重新定义护理标准，而资费调整和不断变化的法规既带来了机会，也带来了限制。透过供应链多元化、策略伙伴关係和敏捷开发流程积极适应这些动态的相关人员，将最有能力塑造外科介入的未来发展轨迹。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 扩展再生细胞治疗平台与生物外科基质相结合用于慢性伤口管理
  • 增加重组生长因子类止血剂在消化器官系统手术中的监管核准
  • 生医材料Start-Ups与领先医疗技术公司扩大合作，加速新型密封剂的开发
  • 针对多重抗药性病原体的下一代抗菌生物可吸收缝合线的开发
  • 透过将3D生物列印技术与生物外科支架结合来加速组织再生
  • 在机器人手术中使用微创止血剂减少术中出血併发症
  • 将人工智慧工具整合到果冻中，以预测患者的出血风险并优化药物选择。
  • 推出可在紧急创伤情况下快速部署的照护现场冻干生物止血剂
  • 成本控制压力促使人们采用合成生物外科黏合剂取代传统的纤维蛋白胶
  • 透过 3D 列印工作流程，实现具有患者专用支架的可客製化生物外科植入

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：果冻市场（依产品类型）

  • 止血剂
  • 密封剂和黏合剂
  • 组织移植

第九章果冻市场（依材料类型）

  • 胶原蛋白蛋白基
  • 纤维蛋白基
  • 明胶基
  • 合成

第 10 章：果冻市场吸收

  • 不可吸收
  • 吸收性
    • 完全可吸收
    • 部分可吸收

第 11 章果冻市场（按应用）

  • 心血管外科
    • 心臟绕道手术
    • 阀门维修
  • 一般外科
    • 疝气修补术
    • 修復伤口
  • 微创手术
    • 内视镜检查
    • 腹腔镜
  • 开放性手术
  • 整形外科
    • 关节重建
    • 脊椎融合手术

第 12 章果冻市场（依最终使用者）

  • 门诊手术中心
  • 医院
  • 专科诊所
    • 牙医诊所
    • 眼科诊所

第 13 章：美洲果冻市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章欧洲、中东和非洲的果冻市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第 15 章：亚太果冻市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Advanced Medical Solutions Group plc
    • Artivion, Inc.
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • BioCer Entwicklungs-GmbH
    • Boston Scientific Corporation
    • Cardinal Health, Inc.
    • Corza Medical GmbH
    • CryoLife, Inc.
    • CSL Limited
    • Hemostasis, LLC
    • Integra LifeSciences Holdings Corporation
    • Johnson & Johnson
    • Kuros Bioscience AG
    • Medtronic plc
    • Pfizer Inc.
    • RTI Surgical, Inc.
    • Samyang Holdings Corporation
    • Sanofi SA
    • Smith & Nephew plc
    • Stryker Corporation
    • Teleflex Incorporated
    • Tissue Regenix Ltd
    • Vivostat A/S

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-AD36CD8982F7

The Biosurgery Market was valued at USD 17.15 billion in 2024 and is projected to grow to USD 18.58 billion in 2025, with a CAGR of 8.48%, reaching USD 27.96 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 17.15 billion
Estimated Year [2025] USD 18.58 billion
Forecast Year [2030] USD 27.96 billion
CAGR (%) 8.48%

Biosurgery has emerged as a pivotal domain within modern healthcare, integrating biologically active materials to support tissue repair, hemostasis, and adhesion in a range of surgical interventions. The growing demand for minimally invasive procedures, coupled with advances in biomaterials science, has propelled this field to the forefront of innovation. Stakeholders are navigating a dynamic environment characterized by evolving regulatory frameworks, heightened cost constraints, and the necessity to demonstrate clinical efficacy across increasingly complex patient populations.

The pace of innovation in biosurgery is being accelerated by cross-disciplinary collaboration among material scientists, engineers, and clinical specialists seeking to optimize performance and safety profiles. Translation of novel collagen, fibrin, and synthetic matrices into scalable products requires rigorous validation and thoughtful integration with existing surgical workflows. Concurrently, regulatory bodies are refining pathways to balance patient safety with timely access, encouraging manufacturers to engage in proactive dialogue and evidence generation.

This executive summary presents a cohesive exploration of the transformative forces shaping the biosurgery market, encompassing technological breakthroughs, policy developments, and shifting provider priorities. It articulates the implications of recent tariff adjustments, dissects core segmentation dimensions across product types, materials, resorbability characteristics, clinical applications, and end user contexts, and surfaces nuanced regional dynamics. Readers will gain strategic clarity on competitive positioning, partnership opportunities, and critical decision points ahead.

Mapping the Paradigm Shifts Driving Biosurgery Innovations and Reconfiguring Competitive Landscapes across Global Healthcare Sectors

In recent years, biosurgery has undergone paradigm-defining transformations driven by the emergence of advanced hemostatic agents, bioadhesives, and tissue graft technologies that offer superior biocompatibility and mechanistic precision. Innovations in fibrin-based sealants and synthetic polymers have unlocked new avenues for effective bleeding control and tissue regeneration. Moreover, multidisciplinary research initiatives are fueling the development of next-generation composites that integrate antimicrobial and growth factor functionalities to streamline postoperative recovery.

Simultaneously, the proliferation of minimally invasive and robotic-assisted techniques has elevated expectations for device design, demanding materials that adhere reliably within constrained working spaces. Surgeons are increasingly seeking solutions that combine ease of deployment with robust performance under physiological stress. This shift is catalyzing partnerships between instrument developers and biomaterial manufacturers aiming to deliver integrated systems that enhance precision, reduce operative times, and minimize patient trauma.

Looking ahead, the convergence of digital health platforms with biosurgery promises to redefine procedural planning, intraoperative guidance, and postoperative monitoring. Data-driven insights derived from real-world evidence studies are informing iterative product refinements, while artificial intelligence algorithms are being explored to predict patient-specific outcomes. These collective advancements are set to elevate biosurgical interventions, fostering a more proactive and personalized approach to tissue repair and hemostasis.

Assessing the Ripple Effects of United States Tariff Adjustments on Biosurgery Supply Chains, Cost Structures, and Strategic Sourcing Practices in 2025

The implementation of revised tariff schedules by United States authorities in 2025 has introduced a new cost dimension for biosurgical materials and devices sourced from international suppliers. These adjustments have heightened scrutiny on import pricing and compelled manufacturers to reevaluate both vendor selection and supply chain architecture. As a result, procurement teams are exploring diversified sourcing models, including nearshoring and regional partnerships, to stabilize input costs and mitigate volatility associated with global trade disruptions.

Beyond direct cost implications, the tariff changes have influenced global competitive dynamics, as domestic producers of hemostats, sealants, and grafts experience a relative advantage in their home markets. International companies are contemplating strategic investments in local manufacturing facilities or contractual alliances to preserve market access and maintain optimal lead times. Such moves underscore a broader trend toward supply chain resilience informed by geopolitical sensitivities and regulatory compliance mandates.

In parallel, tariffs have prompted manufacturers to intensify value engineering efforts, seeking to optimize formulations and reduce reliance on high-cost raw materials without compromising efficacy. Collaborative research agreements and joint ventures are gaining traction as a means to share development costs and expedite the co-creation of innovative products. Ultimately, these strategic adaptations aim to safeguard profitability while ensuring that patients continue to benefit from state-of-the-art biosurgical technologies.

Unveiling Core Segmentation Frameworks Illuminating Diversification Paths in Biosurgery Product Offerings, Materials, Resorbability, Applications, and End User Profiles

Analysis of product categories reveals distinct trajectories for hemostats, sealants and adhesives, and tissue grafts. Hemostatic agents continue to evolve with enhanced absorption kinetics and customizable delivery formats that address bleeding challenges in high-risk procedures. Sealants and adhesives are benefiting from formulations that combine robust bonding strength with biocompatible carrier systems. Tissue graft offerings, including acellular matrices and cellularized constructs, are being refined to improve integration and functional recovery across surgical disciplines.

Material innovations are driving differentiation across collagen-based, fibrin-based, gelatin-based, and synthetic constructs. Collagen matrices are prized for their natural biocompatibility and structural support, while fibrin-derived sealants capitalize on endogenous clotting cascades to reinforce hemostasis. Gelatin-based platforms offer versatile gelation properties that can be tuned for targeted applications, and synthetic polymers provide consistent performance characteristics and reduced immunogenicity. Each material class is undergoing iterative enhancements aimed at optimizing mechanical resilience and degradation profiles.

Resorbability characteristics play a critical role in clinical decision making, with nonresorbable options favored when long-term scaffold stability is required, and resorbable alternatives increasingly adopted to minimize foreign body presence. Fully resorbable materials degrade completely over a predetermined timeframe, supporting temporary support before safe clearance, while partially resorbable systems combine enduring frameworks with degradable components to balance structural needs with eventual absorption. This nuanced spectrum enables tailored therapeutic strategies across patient populations.

Application-specific segmentation underscores the importance of matching device properties to procedural requirements. Cardiovascular surgeries, including bypass operations and valve repairs, demand high-tensile strength adhesives and leak-resistant matrices. General surgical contexts such as hernia repair and wound management leverage lightweight scaffolds and malleable sealants for tissue approximation. Minimally invasive approaches, whether endoscopic or laparoscopic, call for delivery mechanisms compatible with narrow lumens. Orthopedic interventions, spanning joint replacement and spinal fusion, require load-bearing grafts. End user settings vary from ambulatory surgery centers to tertiary hospitals and specialty clinics in dental and ophthalmology practices.

Deciphering Regional Trends Shaping Biosurgery Growth Trajectories across the Americas, Europe Middle East & Africa, and the Asia-Pacific Domain

In the Americas, market growth is being driven by robust investment in healthcare infrastructure and a strong emphasis on minimally invasive procedures. North American regulatory support and reimbursement frameworks are encouraging adoption of premium biosurgical products, while Latin American markets are emerging through targeted public-private partnerships and capacity-building initiatives. This regional diversity presents opportunities for manufacturers that can tailor their portfolios to address varying resource environments and patient access considerations.

Europe, Middle East, and Africa represent a heterogeneous landscape where established Western European markets coexist with evolving economies across the Middle East and North Africa. In Western Europe, cost-containment pressures and rigorous clinical guidelines are prompting value-based adoption of biosurgical solutions. Simultaneously, the Gulf Cooperation Council countries are investing heavily in advanced medical facilities, creating demand for cutting-edge hemostatic and regenerative devices. Market entrants that navigate complex regulatory matrices and foster local collaborations are well positioned to capitalize on this spectrum.

Asia-Pacific is characterized by dynamic growth fueled by expanding healthcare access, rising surgical volumes, and government initiatives to fortify domestic manufacturing capabilities. Established markets such as Japan and Australia demand high-quality, certified products, whereas emerging economies in Southeast Asia and the Indian subcontinent are seeking affordable yet effective biosurgical interventions. Strategic alliances and technology transfer agreements are enabling global players to penetrate these markets, while regional innovators are advancing homegrown solutions tailored to local clinical needs.

Highlighting Strategic Moves and Innovation Pipelines among Leading Biosurgery Companies Forging the Competitive Frontier with Cutting-Edge Solutions and Collaborations

Leading players in the biosurgery arena are pursuing differentiated strategies to maintain competitive advantage. Some have prioritized acquisitions of niche technology firms to bolster their product pipelines, acquiring expertise in novel biomaterials and advanced delivery systems. Others are channeling resources into in-house R&D, establishing dedicated innovation centers to explore next-generation composites and bioactive scaffolds. Collaborations with academic institutions and contract research organizations are also fueling exploratory studies that underpin future product launches.

In addition to internal development, strategic partnerships are reshaping the ecosystem, with some companies entering co-development agreements to streamline regulatory pathways and share commercial risks. Joint ventures with regionally specialized manufacturers are enabling optimized production footprints and faster market access. Meanwhile, smaller, agile firms are carving distinct market positions by concentrating on adjacent therapeutic niches and demonstrating clinical superiority through targeted investigator-initiated trials. These varied approaches are collectively enriching the innovation pipeline.

Competitive dynamics are further influenced by concerted efforts to expand into new geographic territories and clinical segments. Entities with strong distribution networks in upstream specialties are branching into complementary areas, leveraging existing relationships to cross-sell biosurgical offerings. Simultaneously, investment in digital marketing and educational initiatives is equipping healthcare professionals with the knowledge required to adopt advanced technologies. These strategic maneuvers underscore a broader trend toward integrated solutions that transcend traditional product silos.

Empowering Industry Leaders with Pragmatic Recommendations to Navigate Disruption, Leverage Technological Advancements, and Cement Market Leadership in Biosurgery

Investing in adaptive supply chain strategies will be imperative for companies seeking to navigate the evolving trade environment. Establishing multiple sourcing lanes, including regional manufacturing hubs and qualified contract partners, can alleviate price unpredictability and logistical bottlenecks. Proactive engagement with customs authorities and certification bodies will also streamline import processes and prevent costly delays. By building resilience into procurement frameworks, organizations can safeguard operational continuity and protect profit margins against future geopolitical fluctuations.

Prioritizing innovation through cross-functional collaboration can accelerate the translation of novel biomaterials into market-ready solutions. Creating interdisciplinary teams that bring together clinical advisors, engineering specialists, and regulatory affairs experts fosters holistic product development and reduces time to market. In parallel, adopting an agile methodology for iterative design and validation allows for rapid refinement based on user feedback and real-world performance data. This approach ensures that new offerings consistently meet evolving clinician and patient needs.

Expanding strategic footprint within key regions requires tailored commercialization blueprints that reflect local reimbursement dynamics and clinical practices. Companies should invest in market intelligence and stakeholder mapping to identify high-impact entry points and partnership prospects. Cultivating relationships with leading healthcare professionals and opinion leaders can accelerate trial adoption and generate credible evidence to support broader uptake. Through targeted educational initiatives and value demonstration programs, firms can establish sustainable competitive moats in diverse geographies.

Enhancing digital capabilities and data analytics is vital for unlocking deeper insights into procedural outcomes and customer preferences. Implementing robust feedback loops via digital platforms enables continuous product improvement and personalized engagement. Moreover, leveraging predictive analytics to identify emerging clinical trends and procurement patterns empowers commercial teams to proactively position their portfolios. By aligning digital transformation efforts with core business objectives, industry leaders can capitalize on untapped growth opportunities within the biosurgery domain.

Detailing a Rigorous Multimethod Research Methodology Integrating Primary Insights, Secondary Analysis, and Quantitative Modeling to Illuminate Biosurgery Market Realities

This study integrates a multimethod research framework combining primary stakeholder interviews, secondary literature analysis, and quantitative modeling to ensure comprehensive coverage of the biosurgery landscape. In-depth conversations with surgeons, procurement specialists, regulatory experts, and product managers provided first-hand perspectives on unmet needs, innovation drivers, and adoption barriers. Concurrently, a systematic review of published clinical trials, patent filings, and policy white papers enriched the contextual foundation and facilitated triangulation of qualitative inputs with documented evidence.

Quantitative modeling efforts employed robust statistical techniques and sensitivity analyses to explore relationships between key variables such as material properties, procedural volumes, and cost parameters. Data inputs were sourced from peer-reviewed journals, global health organization reports, and public regulatory databases. Regional market maps were constructed using a geospatial approach, enabling visualization of demand concentrations and growth corridors. This quantitative backbone was iteratively validated against primary insights to refine accuracy and coherence.

Quality assurance protocols were implemented throughout the research process, including peer review of analytical outputs, data integrity checks, and validation workshops with external subject matter specialists. Each phase of the methodology adhered to established best practices in market and clinical research, ensuring that conclusions are grounded in both empirical rigor and real-world relevance. This comprehensive approach underpins the credibility of the findings and recommendations presented in this executive summary.

Synthesizing Crucial Findings and Strategic Conclusions to Illuminate the Path Forward for Stakeholders in the Evolving Biosurgery Ecosystem Worldwide

Collectively, the analyses highlighted in this summary illustrate a biosurgery sector at the intersection of rapid technological innovation and shifting economic forces. Advanced materials and application-specific delivery systems are redefining standards of care, while tariff adjustments and regulatory evolutions introduce both opportunities and constraints. Stakeholders who proactively adapt to these dynamics-through supply chain diversification, strategic partnerships, and agile development processes-will be best positioned to shape the future trajectory of surgical interventions.

The segmentation and regional assessments underscore a market characterized by granularity and heterogeneity, where success depends on nuanced understanding of material performance, procedure requirements, and local healthcare landscapes. Leading companies are aligning R&D pipelines with emerging clinical needs and forging collaborative models to accelerate commercial access. As data-driven methodologies and digital tools assume greater prominence, the capacity to generate and act upon actionable intelligence will differentiate market leaders from late adopters.

In sum, this executive summary offers a strategic compass for decision-makers seeking to navigate the complexities of the biosurgery ecosystem. By synthesizing critical insights related to technology trends, policy shifts, segmentation nuances, and competitive behaviors, it equips stakeholders with the clarity needed to make informed investment, development, and commercialization choices. The path forward will demand both visionary leadership and operational excellence to realize the full potential of biosurgical innovations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of regenerative cell therapy platforms combined with biosurgical matrices for chronic wound management
  • 5.2. Increasing regulatory approvals for recombinant growth factor based hemostats in gastrointestinal procedures
  • 5.3. Rising partnerships between biomaterial start ups and large medtech players to fast track novel sealants
  • 5.4. Development of next generation antimicrobial bioabsorbable sutures targeting multidrug resistant pathogens
  • 5.5. Integration of 3d bioprinting techniques with biosurgical scaffolds for accelerated tissue regeneration
  • 5.6. Adoption of minimally invasive hemostatic agents in robotic surgery to reduce perioperative bleeding complications
  • 5.7. Integration of artificial intelligence tools in biosurgery to predict patient bleeding risk and optimize agent selection
  • 5.8. Emergence of point of care lyophilized biologic hemostats for rapid deployment in emergency trauma care settings
  • 5.9. Cost containment pressures driving adoption of synthetic biosurgical adhesives over traditional fibrin sealants
  • 5.10. Shift towards customizable biosurgical implants with patient specific scaffolding via 3d printing workflows

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biosurgery Market, by Product Type

  • 8.1. Introduction
  • 8.2. Hemostats
  • 8.3. Sealants & Adhesives
  • 8.4. Tissue Grafts

9. Biosurgery Market, by Material Type

  • 9.1. Introduction
  • 9.2. Collagen-Based
  • 9.3. Fibrin-Based
  • 9.4. Gelatin-Based
  • 9.5. Synthetic

10. Biosurgery Market, by Resorbability

  • 10.1. Introduction
  • 10.2. Nonresorbable
  • 10.3. Resorbable
    • 10.3.1. Fully Resorbable
    • 10.3.2. Partially Resorbable

11. Biosurgery Market, by Application

  • 11.1. Introduction
  • 11.2. Cardiovascular Surgery
    • 11.2.1. Bypass Surgery
    • 11.2.2. Valve Repair
  • 11.3. General Surgery
    • 11.3.1. Hernia Repair
    • 11.3.2. Wound Repair
  • 11.4. Minimally Invasive Surgery
    • 11.4.1. Endoscopic
    • 11.4.2. Laparoscopic
  • 11.5. Open Surgery
  • 11.6. Orthopedic Surgery
    • 11.6.1. Joint Replacement
    • 11.6.2. Spinal Fusion

12. Biosurgery Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgery Centers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics
    • 12.4.1. Dental Clinics
    • 12.4.2. Ophthalmology Clinics

13. Americas Biosurgery Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Biosurgery Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Biosurgery Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Advanced Medical Solutions Group plc
    • 16.3.2. Artivion, Inc.
    • 16.3.3. B. Braun Melsungen AG
    • 16.3.4. Baxter International Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. BioCer Entwicklungs-GmbH
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. Cardinal Health, Inc.
    • 16.3.9. Corza Medical GmbH
    • 16.3.10. CryoLife, Inc.
    • 16.3.11. CSL Limited
    • 16.3.12. Hemostasis, LLC
    • 16.3.13. Integra LifeSciences Holdings Corporation
    • 16.3.14. Johnson & Johnson
    • 16.3.15. Kuros Bioscience AG
    • 16.3.16. Medtronic plc
    • 16.3.17. Pfizer Inc.
    • 16.3.18. RTI Surgical, Inc.
    • 16.3.19. Samyang Holdings Corporation
    • 16.3.20. Sanofi SA
    • 16.3.21. Smith & Nephew plc
    • 16.3.22. Stryker Corporation
    • 16.3.23. Teleflex Incorporated
    • 16.3.24. Tissue Regenix Ltd
    • 16.3.25. Vivostat A/S

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOSURGERY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOSURGERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. BIOSURGERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. BIOSURGERY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. BIOSURGERY MARKET: RESEARCHAI
  • FIGURE 26. BIOSURGERY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. BIOSURGERY MARKET: RESEARCHCONTACTS
  • FIGURE 28. BIOSURGERY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOSURGERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOSURGERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOSURGERY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS BIOSURGERY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES BIOSURGERY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. GERMANY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 277. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 279. GERMANY BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. GERMANY BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 281. GERMANY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 282. GERMANY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 283. GERMANY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 285. GERMANY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 287. GERMANY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 289. GERMANY BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. GERMANY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 293. FRANCE BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. FRANCE BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. FRANCE BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 299. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 301. FRANCE BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 303. FRANCE BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 305. FRANCE BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 307. FRANCE BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 309. FRANCE BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 311. FRANCE BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. FRANCE BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 313. FRANCE BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 314. FRANCE BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 315. RUSSIA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. RUSSIA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 320. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 321. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 322. RUSSIA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 323. RUSSIA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. RUSSIA BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 325. RUSSIA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 326. RUSSIA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 327. RUSSIA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 328. RUSSIA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 329. RUSSIA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 330. RUSSIA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 331. RUSSIA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 332. RUSSIA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 333. RUSSIA BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. RUSSIA BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 335. RUSSIA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. RUSSIA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 337. ITALY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. ITALY BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 339. ITALY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. ITALY BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 341. ITALY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 342. ITALY BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 343. ITALY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 344. ITALY BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)
  • TABLE 345. ITALY BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. ITALY BIOSURGERY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 347. ITALY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 348. ITALY BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2030 (USD MILLION)
  • TABLE 349. ITALY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 350. ITALY BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2025-2030 (USD MILLION)
  • TABLE 351. ITALY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2024 (USD MILLION)
  • TABLE 352. ITALY BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2025-2030 (USD MILLION)
  • TABLE 353. ITALY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2024 (USD MILLION)
  • TABLE 354. ITALY BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2025-2030 (USD MILLION)
  • TABLE 355. ITALY BIOSURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. ITALY BIOSURGERY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 357. ITALY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 358. ITALY BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
  • TABLE 359. SPAIN BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 360. SPAIN BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 361. SPAIN BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 362. SPAIN BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 363. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2024 (USD MILLION)
  • TABLE 364. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025-2030 (USD MILLION)
  • TABLE 365. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2024 (USD MILLION)
  • TABLE 366. SPAIN BIOSURGERY MARKET SIZE, BY RESORBABLE, 2025-2030 (USD MILLION)